Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin

Full text
Cerda, Alvaro [1] ; Genvigir, Fabiana D. V. [1] ; Arazi, Simone S. [1] ; Hirata, Mario H. [1] ; Dorea, Egidio L. [2] ; Bernik, Marcia M. S. [2] ; Bertolami, Marcelo C. [3] ; Faludi, Andre A. [3] ; Hirata, Rosario D. C. [1]
Total Authors: 9
[1] Univ Sao Paulo, Dept Clin & Toxicol Anal, Sch Pharmaceut Sci, BR-05508900 Sao Paulo - Brazil
[2] Univ Sao Paulo, Univ Hosp, BR-05508900 Sao Paulo - Brazil
[3] Dante Pazzanese Inst Cardiol, Sao Paulo - Brazil
Total Affiliations: 3
Document type: Journal article
Source: Clinica Chimica Acta; v. 411, n. 9-10, p. 631-637, MAY 2 2010.
Web of Science Citations: 19

Background: The SR-BI is a key component on the cholesterol metabolism. Polymorphisms in the SR-BI gene (SCARB1) were related with variations on plasma lipoprotein profile and other risk factors for cardiovascular disease. We tested the relationship of 3 SCARB1 single nucleotide polymorphisms (SNPs) with hypercholesterolemia in a Brazilian population and whether these variants can influence lipid-lowering response to atorvastatin. Methods: c.4G>A, c.726+54C>T and c.1050C>T SNPs and serum concentrations of lipid and apolipoproteins were evaluated in 147 hypercholesterolemic (HC) and 185 normolipidemic (NL) unrelated Brazilian subjects. HC patients were treated with atorvastatin (10 mg/day/4 weeks). Results: Frequencies of SCARB1 polymorphisms were similar between the HC and NL groups (p>0.05). The T allele for c.726+54C>T was associated with higher LDL-c in NL and with higher apoB and apoB/apoAI in HC (p<0.05). HC individuals carrying c.1050C allele carriers (CC and CT genotypes) had lower change of total cholesterol, LDL-c, apoB and apoB/apoAI ratio (p<0.05) than the TT genotype carriers in response to atorvastatin. Conclusion: The SCARB1 polymorphisms are related with variations in serum lipids in the Brazilian population and c.1050C>T SNP is associated with lipid-lowering atorvastatin response. (C) 2010 Elsevier B.V. All rights reserved. (AU)

FAPESP's process: 06/06196-0 - Pharmacogenomics study: effects of hypolipidemic drugs on gene expression of transcription factors involved in cholesterol regulation
Grantee:Rosario Dominguez Crespo Hirata
Support Opportunities: Regular Research Grants